I lead competitive intelligence engagements across the global oncology landscape, translating real-time conference data, pipeline shifts, and stakeholder dynamics into strategies that sharpen positioning and accelerate decisions for biopharma clients.
Apex Strategy Group, a global strategic consultancy with ~500 experts across 7 cities, partnering with 27 of the top 30 biopharma companies worldwide.
Connect on LinkedIn
Connect on LinkedInAs an Engagement Manager at Apex Strategy Group, I sit at the nexus of scientific analysis and competitive strategy in oncology. My work involves designing and leading intelligence programs that track the evolving competitive dynamics across some of the most complex and fast-moving therapeutic areas in biopharma.
From pre-conference planning through real-time intelligence capture to post-congress strategic synthesis, I ensure that every data readout, every KOL reaction, and every pipeline signal is contextualized and translated into actionable strategic recommendations for our biopharma clients.
Working within Apex Strategy's global network spanning London, New York, San Francisco, New Delhi, and beyond, I bring both the analytical rigor of competitive intelligence and the consultative depth needed to inform decisions that shape product strategies from early pipeline through post-launch.
Designing and executing multi-asset CI programs with cross-functional teams, delivering insights that directly influence clinical and commercial strategy.
Comprehensive pre-, peri-, and post-conference intelligence across ASCO, ESMO, AACR, ASH, WCLC, SABCS, and specialty oncology meetings globally.
Managing client relationships and translating complex competitive landscapes into clear, evidence-based recommendations for senior biopharma decision-makers.
Deep understanding of oncology competitive dynamics including immunotherapy, ADCs, bispecifics, radiopharmaceuticals, and precision medicine modalities.
Mapping the competitive, regulatory, and market environment to identify key players, emerging trends, and disruptors, creating holistic, forward-looking competitor dossiers backed by clinical and commercial data.
End-to-end conference coverage from abstract prioritization to real-time insights to post-event strategic synthesis across all major oncology congresses including ASCO, ESMO, AACR, ASH, WCLC, and SABCS.
Facilitating cross-functional workshops that predict competitors' likely actions and develop strategic responses, building organizational confidence through structured threat assessment and scenario analysis.
Dynamic monitoring of competitor pipelines across clinical stages, tracking data readouts, regulatory milestones, label expansions, and commercial strategy signals that impact product positioning.
Capturing and analyzing KOL and healthcare stakeholder perceptions through primary and secondary research to inform positioning, messaging strategy, and clinical differentiation.
Identifying opportunities to maximize competitive advantage across clinical data, value propositions, and franchise strategies, spanning early clinical development through loss of exclusivity.
The premier global oncology meeting where treatment standards shift and drug developers' fortunes are shaped.
Europe's leading oncology congress, increasingly featuring breakthroughs in ADCs, radiopharmaceuticals, and immunotherapy.
A critical forum for earlier-stage cancer science: novel mechanisms, translational breakthroughs, and emerging modalities.
The definitive meeting for hematologic malignancies: leukemias, lymphomas, myeloma, and cell therapies.
The top conference for lung cancer advances, including the competitive PD-1/VEGF inhibitor landscape reshaping treatment paradigms.
The foremost breast cancer conference globally, driving treatment advances from early-stage to metastatic disease.
Focused on immuno-oncology innovation: checkpoint therapies, CAR-T, bispecifics, and emerging combinations.
A premier meeting for hematology research, featuring cutting-edge data on blood cancers and novel cellular therapies.
Aligning coverage objectives with client strategy, identifying key abstracts, competitor assets, KOL activities, and satellite events to maximize intelligence value before the conference begins.
On-ground intelligence gathering across oral sessions, poster presentations, industry symposia, and informal KOL interactions, delivering real-time insights and competitive signals as they emerge.
Translating raw conference intelligence into contextualized strategic analysis, assessing competitive impact, updating landscape assessments, and delivering implications-driven reports that inform cross-functional decision-making.
Maintaining dynamic competitive dashboards, tracking pipeline milestones between congresses, and providing ad-hoc intelligence briefings as market dynamics evolve, ensuring clients are never caught off guard.
NSCLC · Breast · CRC · RCC
AML · CLL · MM · NHL
Checkpoint · CAR-T · Bispecifics
Biomarkers · MRD · Companion Dx
ADCs · Radiopharm · mRNA
Gastric · HCC · Pancreatic · Esophageal
An analysis of the shifting competitive landscape in non-small cell lung cancer, including updated survival data from PD-1/VEGF combinations and the emerging ADC pipeline.
A deep-dive into the antibody-drug conjugate competitive landscape: differentiating profiles, payload mechanisms, and the race for combination regimens across solid tumors.
Why traditional scenario planning underestimates competitor agility in oncology. Intelligence-led war gaming closes the gap between prediction and preparedness.
How targeted radiotherapy is reshaping competitive dynamics in prostate and neuroendocrine tumors, tracking the key players, emerging combinations, and regulatory trajectories.
"John's ASCO briefings are consistently the most actionable intelligence we receive from any partner. She doesn't just report what happened; she tells us what it means for our asset."
"The war gaming workshop she facilitated ahead of our launch was genuinely transformative. The team walked out with clarity on competitive scenarios we hadn't even considered."
"What sets John apart is her ability to synthesize complex scientific data and translate it into strategic implications in real time. Invaluable at major conferences."
Whether it's conference coverage strategy, competitive landscape assessments, war gaming facilitation, or ongoing pipeline intelligence. I'd welcome the conversation. Let's explore how Apex Strategy Group can support your team.